Comparison of the effectiveness of reboxetine versus fluoxetine in patients with atypical depression: A single-blind, randomized clinical trial
Authors:
- 1 November 2006
- journal article
- research article
- Published by Springer Nature in Advances in Therapy
- Vol. 23 (6) , 974-987
Abstract
The atypical subtype of depression appears to be well validated and common, and it is unique among Axis I disorders in theDiagnostic and Statistical Manual of Mental Disorders-Fourth Edition (DSM-IV) in that it includes a personality trait, rejection sensitivity, as a criterion. Drug selection remains a challenge for the clinician who treats patients with this subtype of depression. Noradrenergic antidepressants have been thought to have prominent effects in improving such symptoms as loss of motivation, drive, and energy, which are among the core symptoms of patients with atypical depression. Thus it can be speculated that noradrenergic antidepressants might be superior to serotonergic antidepressants in reducing symptoms of atypical depression. This is the first study to compare the efficacy of fluoxetine, a selective reuptake inhibitor of serotonin, and reboxetine, a selective reuptake inhibitor of norepinephrine, in the treatment of patients with atypical depression. A total of 43 patients with atypical depression according to DSM-IV were randomly assigned to receive fluoxetine or reboxetine over an 8-wk clinical trial. Patients with a Structured Clinical Interview for DSM-IV diagnosis of personality disorder accounted for 54% of those with atypical depression in this sample. Patients with personality disorders were typically young and were unable to maintain a marriage. Adverse effects such as dry mouth, sweating, headache, and urinary retention were more prominent in the reboxetine group than among those given fluoxetine. Although a greater number of patients treated with reboxetine dropped out of treatment, the pattern of response was very similar for both drugs, and both were effective in reducing symptoms of depression. The presence of a personality disorder in patients with atypical depression did not affect the response to either of the antidepressants. These findings might suggest that drugs with norepinephrine or a 5-hydroxytryptamine mechanism of action might act through a common pathway, resulting in a similar response in terms of core symptoms of depression. If tolerability, efficacy, and cost-effectiveness of antidepressants are considered, the best antidepressant is the one that can be used by the patient, whether or not a personality disorder accompanies atypical depression.Keywords
This publication has 26 references indexed in Scilit:
- Which Factors Influence Psychiatrists’ Selection of Antidepressants?American Journal of Psychiatry, 2004
- Atypical depression, atypical temperament and a differential antidepressant response to fluoxetine and nortriptylineDepression and Anxiety, 2004
- Successful treatment of reboxetine-induced urinary hesitancy with tamsulosinEuropean Neuropsychopharmacology, 2002
- A Placebo-Controlled Study of Fluoxetine Versus Imipramine in the Acute Treatment of Atypical DepressionAmerican Journal of Psychiatry, 2000
- Is there a role for a pure noradrenergic drug in the treatment of depression?European Neuropsychopharmacology, 1997
- Moclobemide and fluoxetine in atypical depression: a double-blind trialJournal of Affective Disorders, 1994
- The validity of major depression with atypical features based on a community studyJournal of Affective Disorders, 1992
- A Double-blind Parallel Study Comparing Fluoxetine with Imipramine in the Treatment of Atypical DepressionInternational Clinical Psychopharmacology, 1991
- Sleep of atypical depressivesJournal of Affective Disorders, 1985
- A RATING SCALE FOR DEPRESSIONJournal of Neurology, Neurosurgery & Psychiatry, 1960